Navigation Links
Gene implicated in progression and relapse of deadly breast cancer finding points to potential Achilles' heel in triple negative breast cancer
Date:3/24/2014

NEW YORK (March 24, 2014) Scientists from Weill Cornell Medical College and Houston Methodist have found that a gene previously unassociated with breast cancer plays a pivotal role in the growth and progression of the triple negative form of the disease, a particularly deadly strain that often has few treatment options. Their research, published in this week's Nature, suggests that targeting the gene may be a new approach to treating the disease.

About 42,000 new cases of triple negative breast cancer (TNBC) are diagnosed in the United States each year, about 20 percent of all breast cancer diagnoses. Patients typically relapse within one to three years of being treated.

Senior author Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College, wanted to know whether the gene already understood from her prior work to be a critical regulator of immune and metabolic functions was important to cancer's ability to adapt and thrive in the oxygen- and nutrient-deprived environments inside of tumors. Using cells taken from patients' tumors and transplanted into mice, Dr. Glimcher's team found that the gene, XBP1, is especially active in triple negative breast cancer, particularly in the progression of malignant cells and their resurgence after treatment.

"Patients with the triple negative form of breast cancer are those who most desperately need new approaches to treat their disease," said Dr. Glimcher, who is also a professor of medicine at Weill Cornell. "This pathway was activated in about two-thirds of patients with this type of breast cancer. Now that we better understand how this gene helps tumors proliferate and then return after a patient's initial treatment, we believe we can develop more effective therapies to shrink their growth and delay relapse."

The group, which included investigators from nine institutions, examined several types of breast cancer cell lines. They found that XBP1 was particularly active in basal-like breast cancer cells cultivated in the lab and in triple negative breast cancer cells from patients. When they suppressed the activity of the gene in laboratory cell cultures and animal models, however, the researchers were able to dramatically reduce the size of tumors and the likelihood of relapse, especially when these approaches were used in conjunction with the chemotherapy drugs doxorubicin or paclitexel. The finding suggests that XBP1 controls behaviors associated with tumor-initiating cells that have been implicated as the originators of tumors in a number of cancers, including that of the breast, supporting the hypothesis that combination therapy could be an effective treatment for triple negative breast cancer.

The scientists also found that interactions between XBP1 and another transcriptional regulator, HIF1-alpha, spurs the cancer-driving proteins. Silencing XBP1 in the TNBC cell lines reduced the tumor cells' growth and other behaviors typical of metastasis.

"This starts to demonstrate how cancer cells co-opt the endoplasmic reticulum stress response pathway to allow tumors to grow and survive when they are deprived of nutrients and oxygen," said lead author Dr. Xi Chen, a postdoctoral associate at Weill Cornell, referring to the process by which healthy cells maintain their function. "It shows the interaction between two critical pathways to make the cells better able to deal with a hostile microenvironment, and in that way offers new strategies to target triple negative breast cancer."

Scientists still need to study how those strategies would help women with the disease.

"Obviously we need to know now whether what our group saw in models is what we'll see in patients," said coauthor Dr. Jenny Chang, professor of medicine at Weill Cornell and director of the Houston Methodist Cancer Center. "We are very excited about the prospect of moving this research forward as soon as possible for the benefit of patients."


'/>"/>
Contact: Jen Gundersen
jeg2034@med.cornell.edu
646-317-7402
Weill Cornell Medical College
Source:Eurekalert

Related medicine news :

1. Brain region implicated in emotional disturbance in dementia patients
2. Scripps Research Institute scientists show protein linked to hunger also implicated in alcoholism
3. Enzymes implicated in disease processes attack one another instead of harming body proteins
4. Inhibition of CDK4 might promote lymphoma development and progression
5. Neuropsychological assessment more efficient than MRI for tracking disease progression
6. New therapy to stop progression of fibrosis
7. Vitamin D status associated with multiple sclerosis activity, progression
8. Nonsteroidal anti-inflammatory agent slows rate of progression of neurodegenerative disease
9. Researcher test first-in-class compound for neuroprotection, hope of stopping MS disease progression
10. Stress reduction through meditation may aid in slowing the progression of Alzheimers disease
11. Excessive alcohol consumption increases the progression of atherosclerosis and the risk of stroke
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2017)... ... January 15, 2017 , ... Going above and beyond the ... to better communities around the world by offering the Gensuite team and their ... for team members to become involved in a cause that is bigger than ...
(Date:1/15/2017)... ... January 15, 2017 , ... Accreditation Commission for ... for its specialty care services. Albertsons Companies is the largest national food ... for pharmacy patients. , Accreditation by ACHC reflects Albertsons Companies’ dedication and commitment ...
(Date:1/15/2017)... ... January 15, 2017 , ... ... best physicians in eight Bay Area counties for 2017. Almost 1,000 nominations were ... company managing the award process. Results were announced the magazine’s January 2017 ...
(Date:1/15/2017)... ... January 15, 2017 , ... The Gravity Vault Indoor Rock Climbing Gym ... construction wraps up on the 14,000+ square foot climbing gym, the owners anticipate to ... three in New Jersey and two in New York. With this being its first ...
(Date:1/14/2017)... MN (PRWEB) , ... January 14, 2017 , ... ... present the distinctions among their expanding line of activated charcoal products. With more ... the importance of categorizing their products according to how they cater to specific ...
Breaking Medicine News(10 mins):
(Date:1/16/2017)... 16, 2017  According to Kalorama Information, the ... valued at $4.9 billion for 2016.  The growing ... an aging population with significant diagnostic needs, along ... propelling the market for the modality.  The healthcare ... , focuses on the worldwide market, providing market ...
(Date:1/16/2017)... , January 16, 2017 ... Derivatives Market by Product Type (Methyl, Ethyl, Hydroxyethyl, ... Foods & Beverages, Surface Coatings & Paints), ... by MarketsandMarkets, the market was valued at ... projected to reach USD 6.41 Billion by ...
(Date:1/16/2017)... CRUZ, Calif. , Jan. 16, 2017  Dovetail ... Dovetail™ Hi-C sequencing and assembly service, which yields chromosome-scale ... be presented in a Dovetail-hosted workshop on Jan. 17 ... in San Diego . ... services with the launch of our Dovetail Hi-C offering," ...
Breaking Medicine Technology: